Clinical Trials
9 trialsNCT00856037 2023-09-26
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer
University of Nebraska
Phase 1 Completed
NCT02566993 2021-10-28
ATLANTIS
PharmaMar
Phase 3 Completed
NCT00036790 2019-12-17
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
Phase 1 Completed
NCT00483509 2019-10-04
NGR007
AGC Biologics S.p.A.
Phase 2 Completed
NCT02261805 2018-04-23
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
Georgetown University
Phase 1/2 Terminated
NCT00759824 2015-02-12
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
European Lung Cancer Working Party
Phase 2 Completed
NCT00003847 2013-09-05
VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer
Vertex Pharmaceuticals Incorporated
Phase 2 Terminated
NCT00004930 2013-06-19
Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00020124 2012-03-15
Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
National Institutes of Health Clinical Center (CC)
Phase 1 Completed